期刊文献+

HER-2等病理特征对乳腺癌患者术后转移部位的影响 被引量:2

Effect of HER-2 overexpression and other tumor characteristics on metastasis sites of breast cancer patients after operation
下载PDF
导出
摘要 目的分析乳腺癌术后患者不同转移部位间的差异,从而进一步探索乳腺癌的转移规律。方法回顾性研究了210位乳腺癌术后发生复发转移的患者,并采用多因素分析对不同转移部位患者的临床及肿瘤特征进行比较。结果单因素分析显示非内脏转移(淋巴结、骨转移)患者的平均年龄显著高于内脏转移(肺、肝、脑)者(50.71比46.69,P=0.012);HER-2的阳性率则显著低于内脏转移者(10.6%比25.4%,P=0.05)。Cox回归分析结果显示年龄较大(RR=0.927,95%CI0.877~0.981,P=0.008)、HER-2阴性者(RR=0.253,95%CI0.076~0.836,P=0.024)易倾向非内脏转移;原发灶较大者(RR=3.832,95%CI1.073~13.687,P=0.039)则易向内脏转移。结论不同临床和生物学特征的乳腺癌患者可能会发生不同部位的转移,且转移的机制可能不同。 Objective To analyze the breast caner patients with different sites of recurrence,and to have knowledge of the regular pattern of metastatic breast cancer.Methods We retrospectively analyzed 210 women with metastatic breast cancer.The clinical and biological characteristics were compared between the patients with organ metastases(lung,liver,brain)and non-viscera metastases(lymph node,bone).The Cox regression analysis was used to test the risk factors.Results Univariate analysis indicated that the average of age was significantly lower(50.71 vs 46.69,P=0.012)in the patients with viscera metastases,and the rate of HER-2 overexpression was also significantly higher(10.6% vs 25.4%,P=0.05).Cox regression analysis showed that patients with elder age(RR=0.927 95%CI 0.877-0.981,P=0.008),HER-2 negative overexpression(RR=0.253 95%CI 0.076-0.836,P=0.024)tended to develop non-viscera metastases,while patients with larger tumors(RR=3.832 95%CI 1.073-13.687,P=0.039)tended to develop organ metastases.Conclusions Patients with different clinical and biological characteristics may develop recurrence in different sites.There may be different mechanisms of metastasis for recurrence in different sites.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第2期269-272,共4页 Fudan University Journal of Medical Sciences
关键词 乳腺肿瘤 转移时间 危险因素 breast cancer recurrence risk factor
  • 相关文献

参考文献14

  • 1Selzner M, Morse MA, Vredenburgh JJ, et al. Liver metastases from breast cancer: long-term survival after curative resection[J]. Surgery, 2000, 127 (4) :383 - 389.
  • 2Goldhirsch A, Glick JH, Gelber RD, et al. Meeting high-lights: international expert consensus on the primary therapy of early breast cancer 2005[J]. Ann Oncol, 2005, 16 (10) : 1569- 1583.
  • 3Demicheli R, Bonadonna G, Hrushesky WJ, et al. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour[J]. Breast Cancer Res, 2004, 6 (6):R689- R696.
  • 4Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis [J]. Cancer Res, 2004, 64 (9):2 941 -2 955.
  • 5Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer [J]. Diagn Mol Pathol, 2001, 10 (3) : 139 - 152.
  • 6Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer[J]. J Natl Cancer Inst, 2003, 95 (2):142- 153.
  • 7Emi Y, Kitamura K, Shikada Y, et al. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis[J]. Surgery, 2002, 131 (1 Suppl) :S217- S221.
  • 8Lin NU, Winer EP. Brain metastases: the HER2 paradigm [J]. Clin Cancer Res, 2007, 13 (6) : 1648- 1655.
  • 9Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer[J]. Breast Cancer Res Treat, 1998, 52 (1 - 3) :227 - 237.
  • 10van der Wal BC, Butzelaar RM, van der Meij S, etal. Axillary lymph node ratio and total number of removed lymph . nodes: predictors of survival in stage I and II breast cancer [J]. Eur J Surg Oncol, 2002, 28 (5):481- 489.

同被引文献34

  • 1杜长征,李惠平,侯宽永,李强,赵红梅,王墨培.中国乳腺癌妇女表皮生长因子受体-2表达的Meta分析[J].北京大学学报(医学版),2006,38(2):184-188. 被引量:16
  • 2Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J,2006,12( Suppl 1 ) :70-80.
  • 3Nabholtz JM, Reese DM, Lindsay MA, et al. HER2-positive breast cancer:update on breast cancer international research group trials. Clin Breast Cancer,2002,3 (2) :75-79.
  • 4De Placido S,De Laurentiis M,Carlomagno C,et al. Twenty-year resuits of the Naples GUN randomized trial : predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res, 2003,9 ( 3 ) : 1039-1046.
  • 5Lin NU, Winer EP. Brain metastases: the HER-2 paradigm. Clin Cancer Res,2007,13 ( 6 ) : 1648-1655.
  • 6Kepple J, Henry-Tillman RS, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J surg,2006,192( 1 ) :68-71.
  • 7Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor,progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast ,2008,17 (5) :523-527.
  • 8Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment. Expert Rev Anticancer Ther, 2003,3 ( 3 ) : 403-408
  • 9Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther, 1999,21 (2) :309-318.
  • 10Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cylin D1, and antitumor action. Cancer Res,2002,62(14) :4132-4141.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部